Downregulation of IRS2 in myelodysplastic syndrome: a possible role in impaired hematopoietic cell differentiation

Leuk Res. 2012 Jul;36(7):931-5. doi: 10.1016/j.leukres.2012.03.002. Epub 2012 Mar 31.

Abstract

Insulin receptor substrate 2 (IRS2) is an adaptor protein that associates with the receptor of erythropoietin, insulin-like growth factor 1 and thrombopoietin; however, its role is not known in myelodysplasia. We, herein, report a significantly lower IRS2 expression in MDS cells, compared to normal cells. IRS2 expression was reduced in high-risk, compared to low-risk disease, and positively correlated with neutrophil and platelet counts. IRS2 was upregulated during erythroid differentiation of CD34(+) cells from normal donors and low-risk MDS patients and also during erythroid, granulocytic and megakaryocytic differentiation in cell lines. These results suggest that defective IRS2 expression plays a role in the impaired hematopoietic cell differentiation in MDS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Cell Differentiation / genetics
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / pathology
  • Down-Regulation / genetics
  • Gene Expression Regulation, Leukemic
  • Hematopoiesis / genetics*
  • Hematopoiesis / physiology
  • Hematopoietic Stem Cells / metabolism
  • Hematopoietic Stem Cells / physiology*
  • Humans
  • Insulin Receptor Substrate Proteins / genetics*
  • Insulin Receptor Substrate Proteins / physiology*
  • Leukemia / etiology
  • Leukemia / genetics
  • Leukemia / pathology
  • Middle Aged
  • Myelodysplastic Syndromes / genetics*
  • Myelodysplastic Syndromes / physiopathology
  • Risk Factors
  • Young Adult

Substances

  • IRS2 protein, human
  • Insulin Receptor Substrate Proteins